Drug Discovery

Therachon raises $60m to expand rare disease pipeline

Clinical-stage biotechnology firm Therachon has raised $60m mezzanine financing to advance lead program in achondroplasia and expand rare disease pipeline.

OvaScience, Millendo Therapeutics agree to merge

Biotechnology ccompany OvaScience and clinical-stage biopharmaceutical firm Millendo Therapeutics have signed a merger agreement to create a rare endocrine disease company.

Scancell expands Moditope collaboration with Karolinska Institute

Scancell Holdings, a developer of immunotherapies to treat cancer, has expanded its research collaboration with the rheumatology unit at the Karolinska Institute Sweden.

Takeda collaborates with Ambys on liver disease therapies

Japanese drugmaker Takeda has partnered with biotechnology firm Ambys Medicines to pioneer therapies for the treatment of serious liver diseases.

Apexigen raises $73m to advance immuno-oncology product development

Apexigen, a clinical-stage biopharmaceutical company engaged in the discovery and development of a new generation of antibody therapeutics for oncology, has raised $73m in Series B And Series C financings.

Teneobio, Poseida extend collaboration to develop UniDabs for advanced CAR-T therapies

Teneobio and Poseida Therapeutics have entered into a new research collaboration and licensing agreement to develop novel CAR-T therapies using Teneobio’s heavy chain only domain antibodies (UniDabs).

Oxford BioMedica forms three-way partnership for cystic fibrosis treatment

Oxford BioMedica has collaborated with the UK Cystic Fibrosis Gene Therapy Consortium (GTC) and Imperial Innovations for the development of a long-term therapy to treat patients with cystic fibrosis.

Acadia, Neuren sign North American license deal for Rett syndrome treatment

Acadia Pharmaceuticals and Neuren Pharmaceuticals have signed an exclusive North American license agreement for the development and commercialization of trofinetide for Rett syndrome and other indications.

Biotechnology firm BioTime to secure $43m from Juvenescence

BioTime, a clinical-stage biotechnology company focused on degenerative diseases, has announced a new strategic alignment between AgeX Therapeutics and Juvenescence, for which the company will receive $21.6M in cash and $21.6M in a 7% convertible/redeemable note for 14.4M shares of AgeX Therapeutics.